COVID-19
Abbott released a positive interim analysis of an ongoing clinical study assessing the accuracy of its ID NOW COVID-19 rapid that showed the test that can provide results within 15 minutes has a high degree of specificity and sensitivity.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 22, 2020.
Henry Li, Sorrento’s co-founder, director, president and chief executive officer, did a follow-up interview with BioSpace to discuss the news and speculation surrounding it.
The hopes of billions of people are riding on at least one of the vaccine candidates for COVID-19 currently in clinical development becoming a commercialized preventative treatment for the world. While hopes are high, caution is still being urged by drugmakers and epidemiologists.
PNI will handle development of the vaccine and CanSinoBIO will take care of preclinical testing, human clinical trials, regulatory submissions and commercialization.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 21, 2020.
The U.S. Biomedical Advanced Research and Development Authority (BARDA) paid more than $1 billion to support the development, production and delivery of the vaccine beginning this fall.
In addition to the COVID-19 development, the company plans to use the proceeds toward its pipeline of highly selective direct acting antivirals that target other severe RNA virus infections.
Weeks after Mammoth Biosciences announced its CRISPR-based diagnostics test for COVID-19 had a high degree of specificity even for asymptomatic patients, the company has struck a deal with GSK to accelerate development of the test in hopes of getting them in consumer hands as soon as possible.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 20, 2020.
PRESS RELEASES